30 results found.

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours During Escalation and Weekly in Selected Tumour Types During Expansion, With Repeated Administrations in Patients Showing Clinical Benefit..
BI 836845

Neoplasms Clinical Trial using BIBW 2992; BIBF 1120

Boehringer Ingelheim - Recruiting 18 years or older.
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours..
BIBW 2992; BIBF 1120

Neoplasms Clinical Trial using BI 860585; exemestane; paclitaxel

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours.
BI 860585; exemestane; paclitaxel

Neoplasms Clinical Trial using Cetuximab( erbituxr); Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours.
Cetuximab( erbituxr); Afatinib

Neoplasms Clinical Trial using Carboplatin; BIBW 2992; Paclitaxel; BIBW2992; Bevacizumab

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours.
Carboplatin; BIBW 2992; Paclitaxel; BIBW2992; Bevacizumab

Neoplasms Clinical Trial using volasertib; itraconazole

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours.
volasertib; itraconazole

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours.
BI 853520

Solid Tumours Clinical Trial using selumetinib; rifampicin

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase I Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inducer Rifampicin on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years.
selumetinib; rifampicin

Neoplasms Clinical Trial using bevacizumab [Avastin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study.
bevacizumab [Avastin]

Solid Tumours Clinical Trial using Pharmacokinetic sampling; Olaparib tablet dosing; Itraconazole

AstraZeneca - Recruiting 18 years or older.
- A Non-randomised, Open-label, Sequential, Three-part, Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation, and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours.
Pharmacokinetic sampling; Olaparib tablet dosing; Itraconazole

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, or Brain Tumo Clinical Trial using plerixafor

Sanofi - Recruiting 1 year to 18 years.
- A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants..
plerixafor

Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non Clinical Trial using AZD8186

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours.
AZD8186

Solid Tumours Clinical Trial using Olaparib tablet dosing

AstraZeneca - Recruiting 18 years to 75 years.
- An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment.
Olaparib tablet dosing

Solid Tumours Clinical Trial using Pharmacokinetic sampling; Rifampicin; Olaparib tablet dosing

AstraZeneca - Recruiting 18 years or older.
- A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours.
Pharmacokinetic sampling; Rifampicin; Olaparib tablet dosing

Herpes Zoster Clinical Trial using GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ò18 Years of Age With Solid Tumours Receiving Chemotherapy.
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Placebo

Solid Tumours Clinical Trial using Dabrafenib; Trametinib; Ipilimumab

GlaxoSmithKline - Recruiting 18 years or older.
- Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma.
Dabrafenib; Trametinib; Ipilimumab

Solid Tumours Clinical Trial using Olaparib tablets; Pharmacokinetic sampling; Dietary Fasted; Dietary High Fat

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours.
Olaparib tablets; Pharmacokinetic sampling; Dietary Fasted; Dietary High Fat

Solid Tumours Clinical Trial using Olaparib tablet dosing

AstraZeneca - Recruiting 18 years to 75 years.
- An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment.
Olaparib tablet dosing

Nasopharyngeal Carcinoma Clinical Trial using OPB-51602

National University Hospital, Singapore - Recruiting 21 years or older.
- The Signal Transducer and Activator of Transcription (STAT)3 Pathway and the Development of STAT3 Phosphorylation Inhibitors as Cancer Therapy: Lead-In Phase I Dose-Escalating, Open-Label, Non-Randomised Study of A Weekly Regimen OPB-51602 in Advanced Refractory Solid Tumours With Enrichment Cohorts of Nasopharyngeal Carcinoma Followed By A Biomarker Study Evaluating OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy.
OPB-51602

Solid Tumours Clinical Trial using selumetinib (oral)

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years.
selumetinib (oral)

Cancer of Liver, or Cancer of Pancreas Clinical Trial using Dexmedetomidine

Uppsala University Hospital - Recruiting 18 years to 85 years.
- Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours.
Dexmedetomidine

Advanced Solid Tumours Clinical Trial using PG545

Progen Pharmaceuticals - Recruiting 18 years or older.
- An Open-label, Multi-centre Phase I Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours.
PG545

Solid Tumours of Epithelial Origin, or Metastatic Colorectal Canc Clinical Trial using ColoAd1

PsiOxus Therapeutics Ltd - Recruiting 18 years or older.
- A Clinical Study Of ColoAd1 Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer.
ColoAd1

Advanced Solid Tumours Clinical Trial using AZD0424

Cancer Research UK - Recruiting 18 years or older.
- A Cancer Research UK Phase I Study to Determine the Maximum Tolerated Dose of the Oral Src/Abl Inhibitor AZD0424, and to Identify Tolerable and Effective AZD0424 Combination Regimens for the Treatment of Advanced Solid Tumours.
AZD0424

Solid Tumours Clinical Trial using dabrafenib; trametinib

GlaxoSmithKline - Recruiting 20 years or older.
- A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K Mutation Positive Cutaneous Melanoma (Phase II Part)..
dabrafenib; trametinib

Advanced Solid Tumours Clinical Trial using WX-037; WX-554

Wilex - Recruiting 18 years or older.
- A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors.
WX-037; WX-554

Glioma, or Other Solid Tumours Clinical Trial using 2-hydroxyoleic acid (2-OHOA/2OHOA)

Lipopharma Therapeutics SL - Recruiting 18 years or older.
- A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minervalr) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma.
2-hydroxyoleic acid (2-OHOA/2OHOA)

Solid Tumors, or Non-Hodgkin's Lymphoma Clinical Trial using Efavirenz

Institut Bergoni‚ - Recruiting 18 years to 80 years.
- Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure..
Efavirenz

Neuroblastoma, Brain Tumors, or Solid Tumors Clinical Trial using Temozolomide/Hycamtin (Topotecan)

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 20 years.
- Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours.
Temozolomide/Hycamtin (Topotecan)